



World Association on Dual Disorder 7th World Congress

WADD

World Association
on Dual Disorder


APRIL 28-30
PORTOROZ, SLOVENIA



WADD
Italian Scientific
Committee

NIJZ

National Institute
of Public Health



WADD
Slovenian Scientific
Committee



Europad
European Opioid Addiction Treatment Association
Per aspera ad astra Since 1994
Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE
AUCNS
Association for the Application
of Neuroscience Knowledge
in Social Activity



ALMA MATER
EUROPAEA



NESTOR SZERMAN

WADD PRESIDENT



MERCEDES LOVRECIC

CONGRESS PRESIDENT



ICRO MAREMMANI

EUROPAD PRESIDENT

*Convention Center
Sava Hotels & Resorts*

PROGRAMME



RUBEN BALER
(NIDA, USA)
Dual Disorder and Media



DAVID NUTT
(London, UK)
Psychedelics in the Treatment of
Dual Disorders: Addiction and
Other Mental Disorders



YATAN PAL SINGH BALHARA
(New Delhi, India)
Gaming, Gaming Disorder and
Serious Games in Context of Dual
Disorders



CAROLINE SALOM
(Brisbane, Queensland, AU)
Pain Management and Risk of
Opioid Overdose among People
with Dual Disorders



MAURICE DEMATTEIS
(Grenoble, France, EU)
Pain Treatment in Dual Disorder



LEO SHER
(New York, NY, USA)
Prevention of Suicide in Dual
Depression and Alcohol Use
Disorder.



YIFRAH KAMINER
(Farmington, CT, USA)
Treatment of Youth with Dual
Disorder of Substance Use
Disorder and Depression: A Bi-
Center Study



NESTOR SZERMAN
(Madrid, Spain, EU)
Emotional Dysregulation and Dual
Disorders:
A New Way to Think About Mental
Disorders



LOPEZ RAFAEL MALDONADO
(Barcelona, Spain, EU)
The Epigenetics Involvement
in Addictive Processes



MARTA TORRENS
(Barcelona, Spain, EU)
Depression and Dual Disorders



ICRO MAREMMANI
(Pisa, Italy, EU)
Opioid Agonist Treatment in Dual
Disorder Patients with Special
Reference to Methadone New
Formulations and Long-acting
Buprenorphine Use



NORA VOLKOW
(NIDA, USA)
Update on Prevention and
Treatment of Dual Disorder



WADD 7 World Congress
April 28-30, 2022
Portoroz, Slovenia, EU



WADD
World Association
on Dual Disorder



WADD
Italian Scientific
Committee

Under the Patronage of

National Institute of Public Health
Republic of Slovenia
Ljubljana, Slovenia, EU

Alma Mater Europaea
Ljubljana, Slovenia, EU

Addiction Research Methods Institute
World Federation for the Treatment of Opioid Dependence
New York, NY, USA
NGO with Special Consultative Status with United Nations
Economic and Social Council (ECOSOC)

Promoted by

World Association on Dual Disorder
Madrid, Spain, EU

WADD Slovenian Scientific Committee
Ljubljana, Slovenia

European Opioid Addiction Treatment Association
Pisa, Italy, EU

WADD Italian Scientific Committee
Pisa, Italy, EU

WADD Executive Committee

Nestor Szerman (*Madrid, Spain, EU*) - President
Pedro Ruiz (*RIP*) - Past President
Icro Maremmani (*Pisa, Italy, EU*) - Vice President
Caroline Salom (*Brisbane, QLD, Australia*) - Treasurer
Yatan Balhara (*New Delhi, India*) - Secretary
Ruben Baler (*NIDA, Bethesda, MD, USA*) - Member
Javier Didia (*Buenos Aires, Argentina*) - Member
Leo Sher (*New York, NY, USA*) - Member
Marta Torrens (*Barcelona, Spain, EU*) - Member
Jun Chen (*Shanghai, China*) - Member

WADD Scientific Committee

Rafael Maldonado (*Barcelona, Spain, EU*) - President
Maurice Dematteis (*Grenoble, France, EU*)
Jibrán Khokha (*Dartmouth, Hanover, NH, USA*)
Christian Schutz (*Vancouver, BC, Canada*)
Rodrigo Marin (*Mexico City, Mexico*)
Katherine Mills (*Sidney, NSW, Australia*)
Elena Martín García (*Barcelona, Spain, EU*)
Min Zhao (*Shanghai, China*)
Yifrah Kaminer (*Farmington, CT, USA*)
Lars Lien (*Brumunddal, Norway*)

Local Scientific Committee

Mercedes Lovrecic (*Ljubljana, Slovenia*)
Barbara Lovrecic (*Ljubljana, Slovenia*)
Rok Tavcar (*Ljubljana, Slovenia*)
Mojca Zvezdana Dernovšek (*Ljubljana, Slovenia*)
Mirjana Radovanovic (*Ljubljana, Slovenia*)
Maja Rus Makovec (*Ljubljana, Slovenia*)

Organizing Committee

Ti.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy
Phone +39 0564412038 - Fax +39 0564412485
E-mail: giusi@tigicongress.com

AU-CNS, Via XX Settembre, 83 - 55045 PIETRASANTA, LU, Italy
Phone +39 0584790073
E-mail: info@aucns.org

PROGRAM

FRIDAY APRIL 28, 2023

TIME	ABSTRACT NO	
 INVITED ORAL PRESENTATIONS		
10:30 12:00	ROOM A	WADD INVITED ORAL PRESENTATIONS <i>Chair: Fabio Curcio (Naples, Italy, EU)</i>
10:30 11:00	OP-1	FABIO CURCIO (Naples, Italy, EU) - Screening and Treatment of Hcv in Dual Disorder Patients
11:00 11:30	OP-2	MUSTAFA AL'ABSI (Duluth, MN, USA) - Biobehavioral and Affective Responses to Acute Stress in Dual Substance Users: Impact of Nicotine and Cannabis Co-Use
11:30 12:00	OP-3	PINHAS DANNON (Jerusalem, Israel, IL) - The Effectiveness of Electroconvulsive Therapy in Substance Use Disorder at Pharmacological Treatment Failure Major Depression
10:30 12:00	ROOM B	WADD INVITED ORAL PRESENTATIONS <i>Chair: Einat Peles (Tel Aviv, Israel)</i>
10:30 11:00	OP-4	ALICE DESCHENAU (Villejuif, France, EU) - Data on the First Cohort of Patients Treated with Long-Acting Buprenorphine in Subcutaneous Depot in a French Addiction Center
11:00 11:30	OP-5	ARI KASKI (Kuopio, Finland, EU) - Reasons for not Entering Opioid Agonist Treatment - A Survey among High Risk Opioid Users in Finland
11:30 12:00	OP-6	EINAT PELES (Tel Aviv, Israel, IL) - Genetic and Environment Factors Predicting Outcome of Patients in Methadone Maintenance Treatment
10:30 12:00	ROOM C	WADD INVITED ORAL PRESENTATIONS <i>Chair: Albrecht Ulmer (Stuttgart, Germany, EU)</i>
10:30 11:00	OP-7	PINHAS DANNON (Jerusalem, Israel, IL) - Risky Decision-Making in Schizophrenia: Examination of Association between Smoking, Substance Use and Performance on the Iowa Gambling Test
11:00 11:30	OP-8	ROSA BLANCA SAURAS QUETCUTI (Barcelona, Spain, EU) - From Methamphetamine Induced Psychosis to Schizophrenia: A Study of Diagnostic Stability in Dual Disorder Units of Parc De Salut Mar in Barcelona
11:30 12:00	OP-9	ALBRECHT ULMER (Stuttgart, Germany, EU) - Treatment of a Patient with Fasd (Fetal Alcohol Spectrum Disorder) and AUD (Alcohol Use Disorder) with DHC (Dihydrocodeine)
10:30 12:00	ROOM D	S01 - THE THERAPEUTIC EFFECT OF OXYTOCIN ON ADDICTION AND CO-OCCURRING DUAL DISORDERS <i>Chair: Sara Jafari (Tehran, Iran)</i>
10:30 11:00	S01-1	SARA JAFARI (Tehran, Iran) - The Therapeutic Effect of Oxytocin on Addiction and Co-Occurring Dual Disorders
11:00 11:30	S01-2	SHAHRAM NADERI (Tehran, Iran) - Effects of Oxytocin on Modulating Neuromodulators and Brain Neurotransmitters in Addiction and Co-Occurring Dual Disorders
11:30 12:00	S01-2	SHAHRAM NADERIMAZEJIN (Tehran, Iran) - A Critique on the Way Oxytocin Is Administered in Studies Related to Addiction and Co-Occurring Dual Disorders
12:00 13:00	LUNCH ON YOUR OWN	

FRIDAY APRIL 28, 2023

TIME	ABSTRACT NO	
○ WADD SYMPOSIA		
13:00 14:30	ROOM A	S02 - AGONIST OPIOID LONG TERM FORMULATIONS AND DUAL DISORDER <i>Chair: Chair: Maurice Dematteis (Grenoble, France, EU)</i>
13:00 13:30	S02-1	MARTA TORRENS (Barcelona, Spain, EU) - Stigma and Gender in Addiction: New Therapeutic Opportunities
13:30 14:00	S02-2	MAURICE DEMATTEIS (Grenoble, France, EU) - Back to the Future: New Galenics for an Old Medication as a Therapeutic Opportunity for Dual Disorder Patients
14:00 14:30	S02-3	LORENZO SOMAINI (Biella, Italy, EU) - Agonist Opioid Long-term Formulations: A New Therapeutic Opportunity for Dual Disorder patients
13:00 14:30	ROOM B	S03 - DISENTANGLING DUAL DISORDERS, THE RELEVANCE OF EXPERIMENTAL MODELS TO UNDERSTAND HUMAN ADDICTIVE BEHAVIORS: CHOICE, BINGE, COMPULSION AND BEYOND <i>Chair: Serge Ahmed (Bordeaux, France, EU)</i>
13:00 13:30	S03-1	SERGE AHMED (Bordeaux, France, EU) - Choosing under the Influence: How Cocaine Begets Cocaine Choice
13:30 14:00	S03-2	MICKAEL NAASSILA (Amiens, France, EU) - Preclinical Models of Alcohol Use Disorder and Dual Disorders: No More Lost in Translation
14:00 14:30	S03-3	SEBASTIEN CARNICELLA (Grenoble, France, EU) - Studying Specific Dimensions of Addiction in Preclinical Models for a Better Clinical Translationality: The Case of Compulsive Alcohol Use
○ INVITED ORAL PRESENTATIONS		
13:00 14:30	ROOM C	WADD INVITED ORAL PRESENTATIONS <i>Chair: Jakob Krarup (Roskilde, Denmark, EU)</i>
13:00 13:30	OP-10	SAMIR SHIMON KASPER (Zenica, Bosnia and Herzegovina, BA) - Psychiatric Addiction or Addiction Psychiatry Adequate Treatment of Opiate Addicts with Dual Disorder
13:30 14:00	OP-11	JAKOB KRARUP (Roskilde, Denmark, EU) - VR Assisted CBT in the Treatment of Social Anxiety among People with Dual Disorder: An Exploratory Study of Acceptance, Feasibility and Preliminary Efficacy
14:00 14:30	OP-12	KHADIJA KARJOUH (Kenitra, Maroc, MA) - Early Maladaptive Schemas and Anxiodepressive Disorders among Psychoactive Substance Users in Rabat
13:00 14:30	ROOM D	WADD INVITED ORAL PRESENTATIONS <i>Chair: Zoe Friedmann (Berlin, Germany, EU)</i>
13:00 13:30	OP-13	ZOE FRIEDMANN (Berlin, Germany, EU) - What Encourages or Deters People Living with Opioid Use Disorder from Initiating Supervised Injectable Opioid Treatment? Findings from a Qualitative Cross-Sectional Study in Two German Treatment Facilities
13:30 14:00	OP-14	BARBARA LOVRECIC (Ljubljana, Slovenia, EU) - Trends of Hospital Admissions for Mental and Behavioural Disorders Due to Acute Intoxications by Alcohol, Cannabinoids, Benzodiazepines and Heroin among Adolescent and Young Adults in Slovenia in Period 1999–2019: The Impact of Economic Crisis
14:00 14:30	OP-15	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Trends of Hospitalization for Acute Alcohol Intoxication in Slovenian Children and Adolescents with and without Dual Disorder. Implications for a Correct Intervention

FRIDAY APRIL 28, 2023

TIME	ABSTRACT NO	
○ SATELLITE SYMPOSIUM		
14:30 16:00	ROOM A	S04 - NEW APPROACH IN THE TREATMENT OF DUAL DISORDER (In collaboration with RECORDATI) <i>Chair: Nestor Szerman (Madrid, Spain, EU)</i>
14:30 15:00	S04-1	CARLOS RONCERO (Salamanca, Spain, EU) - The Future of the Management of Dual Disorder
15:00 15:30	S04-2	NESTOR SZERMAN (Madrid, Spain, EU) - Cariprazine in Patients with Schizophrenia and Cannabis Use Disorder
15:30 16:00	S04-3	DOMENICO DE BERARDIS (Teramo, Italy, EU) - Clinical Experience with Cariprazine in Psychotic Subjects with Substance Use Disorder
○ INVITED ORAL PRESENTATIONS		
14:30 16:00	ROOM B	WADD INVITED ORAL PRESENTATIONS <i>Chair: Alexander Kantchev (Sofia, Bulgaria, EU)</i>
14:30 15:00	OP-16	ALEXANDER KANTCHEV (Sofia, Bulgaria, EU) - The Concept of Liaison in Addiction Psychiatry
15:00 15:30	OP-17	TSVETANA STOYKOVA (Sofia, Bulgaria, EU) - Borderline Personality Disorder and Drinking Problems in Female Patients - Psychotherapeutic Understanding and Mechanisms of Change
15:30 16:00	OP-18	CHRISTOPHER WURM (Prospect East, Australia, AU) - The Burden of Alcohol-Related Brain Damage. How Much Does the General Public Understand the Risk? How Can We Improve Recognition in Clinical Care?
○ WADD SYMPOSIA		
14:30 16:00	ROOM C	S05 - TREATMENT OF DUAL DISORDER A-ADHD <i>Chair: Angelo G.I. Maremmi (Viareggio, Italy, EU)</i>
14:30 15:00	S05-1	MARCO MAIELLO (Massa, Italy, EU) - Challenges of treating ADHD with comorbid substance use disorder: considerations for the clinician
15:00 15:30	S05-2	ANGELO G. I. MAREMMANI (Viareggio, Italy, EU) - Adult-Attention Deficit Hyperactive Disorder Seems Not to Influence the Outcome of an Enhanced Agonist Opioid Treatment
15:30 16:00	S05-3	ALESSANDRO PALLUCCHINI (Pisa, Italy, EU) - Influence of Substance Use Disorder on Treatment Retention of Adult-Attention-Deficit/Hyperactive Disorder Patients
14:30 16:00	ROOM D	S06 - IS IT ADHD AND/OR AUTISM AND/OR PERSONALITY DISORDER? RELEVANCE OF THE DIMENSIONAL APPROACH IN THE CLINICAL PRACTICE <i>Chair: Maurice Dematteis (Grenoble, France, EU)</i>
14:30 15:00	S06-1	SÉBASTIEN WEIBEL (Strasbourg, France, EU) - Adhd and Borderline Personality Disorder: An Incidental Association or a Developmental Relationship?
15:00 15:30	S06-2	LUCIE PENNEL (Grenoble, France, EU) - Pragmatic Strategies to Assess and Treat Complex Hybrid Clinical Situations in Addiction Medicine
15:30 16:00	S06-3	JULIEN DUBREUCQ (Saint Etienne, France, EU) - Autism Spectrum Disorder and Co-Occurring Psychiatric and Addictive Disorders: The Invisible but Determinative Disorder? Implication for the Treatment

FRIDAY APRIL 28, 2023

TIME	ABSTRACT NO	
○ OPENING CEREMONY		
	ROOM A	CONFERENCES <i>Chairs: Mercedes Lovrecic (Ljubljana, Slovenia, EU)</i>
16:15 16:30	CF-0	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Conference opening
16:30 17:30	CF-1	NORA VOLKOW (NIDA, USA) - Update on Prevention and Treatment of Dual Disorder
17:30 18:00	CF-2	RUBEN BALER (NIDA, USA) - Dual Disorder and Media
18:00 19:00	CF-3	NESTOR SZERMAN (Madrid, Spain, EU) - Emotional Dysregulation and Dual Disorders: A new way to think about Mental Disorders
19:00 20:00	CF-4	ICRO MAREMMANI (Pisa, Italy, EU) - Opioid Agonist Treatment in Dual Disorder Patients with Special Reference to Methadone New Formulations and Long-acting Buprenorphine Use
○ WELCOME COCKTAIL AND WADD AWARD 2023		
20:00		<i>Chairs: Nestor Szerman (Madrid, Spain, EU), Icro Maremmanni (Pisa, Italy, EU), and Mercedes Lovrecic (Ljubljana, Slovenia, EU)</i>
		WADD AWARD 2023
		TO BE AWARDED: MOJCA ZVEZDANA DERNOVŠEK (Ljubljana, Slovenia, EU)
		LILJANA IGNJATOVA (Skopje, North Macedonia)
		ALEXANDER KANTCHELOV (Sofia, Bulgaria, EU)
		  
		<i>Mojca Dernovsek Liljana Ignjatova Alexander Kantchev</i>
		 
		PISA ROVAI SCHOLARS AWARD <i>"The Luca Rovai Award"</i> "Dedicated to all those who dream of a better world for drug addicts"

Best poster Rovai Scholars award

SATURDAY APRIL 29, 2023

TIME	AB- STRACT NO	
 WADD SYMPOSIA		
8:00 9:30	ROOM A	S07 - INTERACTION BETWEEN THE SUBSTANCE AND NON-SUBSTANCE USE DISORDERS AND THE DISSOCIATIVE DISORDERS. CLINICAL OBSERVATION AND PSYCHOLOGICAL INTERVENTION <i>Chair: Emanuela Atzori (Rome, Italy, EU)</i>
8:00 8:30	S07-1	EMANUELA ATZORI (Rome, Italia, EU) - Dissociation as Representation of Altered States of Consciousness at the Base of Sensation Seeking in Young People and Adults
8:30 9:00	S07-2	ILARIO RITACCO (Rome, Italia, EU) - Dissociation as Representation of Altered States of Consciousness and Its Relation with the Substance Use Disorder. Diagnostic Caveats
9:00 9:30	S07-3	LUDOVICA COSTANTINO (Rome, Italy, EU) - Dissociation in Anorexia -Bulimia Nervosa and Treatment During Covid-19 Pandemic
8:00 9:30	ROOM B	S08 - THE CHALLENGES OF DUAL DISORDERS <i>Chair: Liljana Ignjatova (Skopje, North Macedonia)</i>
8:00 8:30	S08-1	LILJANA IGNJATOVA (Skopje, North Macedonia) - “Scotoma” of Substance Use Disorders among Psychiatrists
8:30 9:00	S08-2	GORDANA KITEVA TRENCEVSKA (Skopje, North Macedonia) - The Challenges of Substance Use Disorders in Neurology
9:00 9:30	S08-3	ADA HOČEVAR GROM (Ljubljana, Slovenia, EU) - The Challenges of Dual Disorder from Public Health Perspective
8:00 9:30	ROOM C	S09 - DUAL DISORDER TREATMENT ACROSS THREE CONTINENTS: INSIGHTS FROM CURRENT APPROACHES, AVAILABLE RESOURCES, AND RECOMMENDATIONS <i>Chair: Christian Schutz (Vancouver, BC, Canada)</i>
8:00 8:30	S09-1	YATAN PAL SINGH BALHARA (New Delhi, India) - Insight from India
8:30 9:00	S09-2	VIJAY SEETHAPATHY (Vancouver, BC, Canada) - Insight from Canada
9:00 9:30	S09-3	MARTA TORRENS (Barcelona, Spain, EU) - Insight from Europe
8:00 9:30	ROOM D	S10 - ASSERTIVE COMMUNITY TREATMENT FOR PERSONS WITH DUAL DISORDER. RESULTS FROM A RESEARCH PROJECT IN NORWAY. <i>Chair: Anne Landheim (Hamar, Norway)</i>
8:00 8:30	S10-1	ANNE LANDHEIM (Hamar, Norway) - Patient Characteristics and Outcome Measures Concerning Functional Level, Problematic Use of Substances and Quality of Life in Patients with and without Dd in Act and Fact-Teams in Norway
8:30 9:00	S10-2	BARD GRONSTOL (Vestfol, Norway, NOR) - United we stand –divided we fall – a collaborative treatment model for persons with concurrent substance abuse and mental health disorders
9:00 9:30	S10-3	EVA BREKKE (Hamar, Norway, NOR) - Dual Disorder, Coercion and Medication in Flexible Assertive Community Treatment: A Qualitative Study of First-Person Experiences
 CONFERENCE		
9:30 10:30	ROOM A	CONFERENCE 2 <i>Chairs: Mercedes Lovrecic (Ljubljana, Slovenia, EU)</i>
	CF-5	YATAN PAL SINGH BALHARA (New Delhi, India) - Gaming, Gaming Disorder and Serious Games in context of dual disorders

SATURDAY APRIL 29, 2023

TIME	AB- STRACT NO	
○ WADD SYMPOSIA		
10:30 12:00	ROOM A	S11 - NEURODEVELOPMENTAL AND NEURODEGENERATIVE VARIANTS <i>Chair: Icro Maremmani (Pisa, Italy, EU)</i>
10:30 11:00	S11-1	ALESSANDRO PALLUCCHINI (Pisa, Italy, EU) - Symptomatological Variants and Related Clinical Features in A-ADHD
11:00 11:30	S11-2	VINCENZA SPERA (Mendrisio, Switzerland) - A-ADHD: Patterns of Use, Related Clinical Features and Different Impact of Cannabis, Cocaine and Alcohol Use
11:30 12:00	S11-3	MANUEL GLAUCO CARBONE (Varese, Italy, EU) - Cocaine use and neurodegenerative diseases
10:30 12:00	ROOM B	S12 - DUAL DISORDERS. THE CURRENT STATE OF SERVICES AND RESEARCH IN INDIA <i>Chair: Yatan Pal Singh Balhaar (New Delhi, India)</i>
10:30 11:00	S12-0	YATAN PAL SINGH BALHARA (New Delhi, India) - Services for Dual Disorders in India
11:00 11:30	S12-2	SIDDHARTH SARKAR (New Delhi, India) - Research on Dual Disorders in India
11:30 12:00	S12-3	VAIBHAV PATIL (New Delhi, India) - Initiatives Taken to Strengthen the Focus in Dual Disorders in India
10:30 12:00	ROOM C	S13 - THE IMPACT OF THE COVID-19 PANDEMIC ON PERSONS WITH CO-OCCURRING MENTAL HEALTH AND SUBSTANCE USE DISORDERS <i>Chair: Marja Leonhardt (Brumunddal, Norway)</i>
10:30 11:00	S13-0	MARJA LEONHARDT (Brumunddal, Norway) - The Impact of the Covid-19 Pandemic on Persons with Co-Occurring Mental Health and Substance Use Disorders
11:00 11:30	S13-2	EVA BREKKE (Brumunddal, Norway, NOR) - Citizenship and Recovery among Service Users in Norwegian Flexible Assertive Community Treatment (Fact) Teams During the Pandemic
11:30 12:00	S13-3	JOAKIM HAUGE (Brumunddal, Norway, NOR) - Experience of a Municipal Covid-19-Unit - Challenges and Key Measures in Providing Care for Persons with Co-Occurring Mental Health and Substance Use Disorder
10:30 12:00	Room D	S14 - INFLAMMATION IN DUAL DISORDERS : FROM DIFFERING PATHWAYS TO FINAL DESTINATIONS <i>Chair: Lisa Blecha (Villejuif, France, EU)</i>
10:30 11:00	S14-0	LISA BLECHA (Villejuif, France, EU) - Viral Infections, Inflammation and Dual Disorders
11:00 11:30	S14-2	DERVAUX ALAIN (Etampes, France, EU) - Inflammation in Psychiatric Disorders: Does Tobacco Smoking Have a Role?
11:30 12:00	S14-3	ROMEO BRUNO (Villejuif, France, EU) - Cannabis Use and Cessation: Its Impact on Inflammation in Psychosis Patients
○ CONFERENCE		
12:00 13:00	ROOM A	CONFERENCE 3 <i>Chair: Yatan Pal Singh Balhaar (New Delhi, India)</i>
	CF-6	CAROLINE SALOM (Brisbane, Queensland, Australia) - Pain management and risk of opioid overdose among people with dual disorders
13:00 14:00	LUNCH ON YOUR OWN	

SATURDAY APRIL 29, 2023

TIME	ABSTRACT NO	
14:00 15:30	ROOM A	WADD GENERAL ASSEMBLY
○ WADD SYMPOSIA		
15:30 17:00	ROOM A	S15 - JOFRÉ PROGRAM: CLINICAL PRACTICAL AND RESEARCH TRAINING IN DUAL DISORDERS IN SPAIN <i>Chair: Gonzalo Haro (Castellón de la Plana, Spain, EU)</i>
15:30 16:00	S15-1	GONZALO HARO (Castellón de la Plana, Spain, EU) - Castellón, 13 Years Training Latin American Residents in Dual Disorders
16:00 16:30	S15-2	CARLOS RONCERO (Salamanca, Spain, EU) - Clinical Practical and Research Option for Dual Disorder Learning in Salamanca
16:30 17:00	S15-3	PABLO VEGA (Madrid, Spain, EU) - A Multicenter Option for Dual Disorders Clinical Practical Learning in Madrid
15:30 17:00	ROOM B	S16 - THE PSYCHEDELIC RENAISSANCE: THEORY, RESEARCH AND CLINICAL PRACTICE <i>Chair: Christian Schutz (Vancouver, BC, Canada)</i>
15:30 16:00	S16-1	CHRISTIAN SCHUTZ (Vancouver, Canada) - Update on Results and Ongoing Studies of Psychedelic Research
16:00 16:30	S16-2	LOUISE PENZENSTADLER (Geneva, Switzerland) - The Geneva Compassionate Use Program
16:30 17:00	S16-3	DANIELE ZULLINO (Geneva, Switzerland) - The Psychedelic Experience as a Special Mode of Exposure Therapy
15:30 17:00	ROOM C	S17 - NEUROBIOLOGICAL UNDERPINNINGS OF INDIVIDUAL VARIABILITY IN ADDICTION: INSIGHTS FROM CLINICAL AND PRECLINICAL RESEARCH <i>Chair: Elena Martin-Garcia (Barcelona, Spain, EU)</i>
15:30 16:00	S17-1	INIGO RUIZ DE AZUA (Mainz, Germany, EU) - Cannabinoid type 1 receptor in CamKII+ neurons drives hedonic feeding: implications in obesity, binge eating and food addiction
16:00 16:30	S17-2	NAZZARENO CANNELLA (Camerino, Italy, EU) - Vulnerability to Opioid Use Disorders (Oud) in Nih Heterogeneous-Stock (Hs) Rats and Genetically Selected Marchigian Sardinian Alcohol-Preferring (Msp) Rats
16:30 17:00	S17-3	ELENA MARTIN-GARCIA (Barcelona, Spain, EU) - Neurobiological Signatures Associated with Vulnerability to Food Addiction in Mice and Humans with a Gender Perspective
15:30 17:00	ROOM D	S00 - WADD DEBATE FORUM <i>Chair: Yatan Pal Singh Balhaar (New Delhi, India)</i>
18:00 19:00	ROOM D	WADD SCIENTIFIC COMMITTEE MEETING
○ CONFERENCES		
17:00 18:00	ROOM A	CONFERENCE 4 <i>Chair: Christian Schutz (Vancouver, BC, Canada)</i>
	CF-7	LEO SHER (New York, NY, USA) - Prevention of suicide in dual depression and alcohol use disorder
18:00 19:00	ROOM A	CONFERENCE 5 <i>Chair: Carlos Roncero (Salamanca, Spain, EU)</i>
	CF-8	MARTA TORRENS (Barcelona, Spain, EU) - Depression and Dual Disorders
20:00		SOCIAL DINNER*
		* Tickets are available for all delegates

SUNDAY APRIL 30, 2023

TIME	ABSTRACT NO	
○ WADD SYMPOSIA		
8:30 10:00	ROOM A	S18 - OPIOIDS AS NEW PHARMACOLOGICAL AVENUES IN ALCOHOL USE DISORDER: FROM BEDSIDE TO BENCHSIDE, AND BACK TO PATIENTS <i>Chair: Albrecht Ulmer (Stuttgart, Germany, EU)</i>
8:30 9:00	S18-1	ALBRECHT ULMER (Stuttgart, Germany, EU) - Opioids for Alcohol Use Disorder Patients: The Path of an Idea
9:00 9:30	S18-2	MAURICE DEMATTEIS (Grenoble, France, EU) - The Neuroscience-Based Nomenclature: Rethinking Opioid Pharmacology to Better Treat Alcohol Use Disorder and Dual Disorders
9:30 10:00	S18-3	ROBERTO CICCOCIOPPO (Camerino, Italy, EU) - Addressing Opioid Receptors to Treat Alcohol Use Disorder
8:30 10:00	ROOM B	WADD INVITED ORAL PRESENTATIONS <i>Chair: Alice Deschenau (Villejuif, France, EU)</i>
8:30 9:00	OP-19	ALICE DESCHENAU (Villejuif, France, EU) - Clinical and Social Feedback from Patients Who Initiated Long-Acting Buprenorphine in a French Addiction Center
9:00 9:30	OP-20	DANIEL FEINGOLD (Nataf, Israel, IL) - The Association between Moral Injury and Cannabis Use Disorder among Israeli Combat Veterans: Evidence from a Multi-Methods Study
9:30 10:00	OP-21	JUAN J. FERNANDEZ-MIRANDA (Gijón, Spain, EU) - Clinical and Treatment Differences in Patients with Dual Diagnoses in Mental Health or Addiction Settings
8:30 10:00	ROOM C	WADD INVITED ORAL PRESENTATIONS <i>Chair: Or Gliksberg (Nataf, Israel)</i>
8:30 9:00	OP-22	OR GLIKSBERG (Nataf, Israel) - Negative Experiences of Patients Who Use Medicinal Cannabis: A Systematic Review and Qualitative Investigation
9:00 9:30	OP-23	KUNHUA LEE (Hsinchu City, Taiwan) - The Relationships between Depressive Symptoms, Shame and Guilt, Positive Outcome Expectancy, and Addiction in a Population of Patients with Methadone Replacement Treatment in Taiwan
9:30 10:00	OP-24	BERNADETTE MARSON (Fredonia, NY, USA) - Treating Dual Diagnosis Disorders Via Telehealth: Current Directions in Integrated Comprehensive Care
8:30 10:00	ROOM D	S19 - THE NEED FOR NEW APPROACHES IN HARM REDUCTION <i>Chair: Nader Charkhgard (Tehran, Iran)</i>
8:30 9:00	S19-1	NADER CHARKHGARD (Tehran, Iran, IR) - The Need for New Approaches in Harm Redaction
9:00 9:30	S19-2	SAMAN NIKNEJAD (Tehran, Iran, IR) - Necessity of Mediation the Future of Harm Redaction
9:30 10:00	S19-3	PAYMAN RAAD (Tehran, Iran, IR) - Comorbidities of Addiction and Mediation
○ CONFERENCES		
10:00- 11:00	ROOM A	CONFERENCE 6 <i>Chair: Mario Miccoli (Pisa, Italy, EU)</i>
	CF-9	MAURICE DEMATTEIS (Grenoble, France, EU) - Pain treatment in Dual Disorder
10:00 11:00	ROOM B	CONFERENCE 7 <i>Chair: Mojca Dernovsek (Ljubljana, Slovenia, EU)</i>
	CF-10	LOPEZ RAFAEL MALDONADO (Barcelona, Spain, EU) - The Epigenetics Involvement in Addictive Processes

SUNDAY APRIL 30, 2023

TIME	ABSTRACT NO	
○ WADD SYMPOSIA		
11:00-12:30	ROOM A	S20 - CONVERGENCIES BETWEEN GAMBLING DISORDER AND PARKINSON'S DISEASE <i>Chair: Lubomir Okruhlica (Bratislava, Slovakia, EU)</i>
11:00-11:30	S20-1	LUBOMIR OKRUHLICA (Bratislava, Slovakia, EU) - Title to be confirmed
11:30-12:00	S20-2	ADAM KURILLA (Bratislava, Slovakia, EU) - Methamphetamine Use and Problem Gambling
12:00-12:30	S20-3	ZUZANA KAMENDY (Bratislava, Slovakia, EU) - Gambling Disorder in Patients Treated for Methamphetamine Use
11:00-12:30	ROOM B	S21 - NOVEL PSYCHOACTIVE SUBSTANCES AND MENTAL DISORDERS <i>Chair: Mercedes Lovrecic (Ljubljana, Slovenia, EU)</i>
11:00-11:30	S21-1	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Novel Psychoactive Substances Induced Dual Disorders
11:30-12:00	S21-2	MATTEO PACINI (Pisa, Italy, EU) - Mega-dose Benzodiazepines Addiction: A New Stand-alone
12:00-12:30	S21-3	SARAH VECCHIO (Biella, Italy, EU) - Novel Psychoactive Substances: Remarks on the Care System and Gender Differences
11:00-12:30	ROOM C	WADD INVITED ORAL PRESENTATIONS <i>Chair: Petr Nevsimal (Praha, Czech Republic, EU)</i>
11:00-11:30	OP-25	PETR NEVŠÍMAL (Praha, Czech Republic, EU) - Integrated Treatment for Clients with Dual Diagnosis
11:30-12:00	OP-26	SOLVEJ MÅRTENSSON (Roskilde, Denmark, EU) - Time Trends in Co-Occurring Substance Use and Psychiatric Illness (Dual Disorder) from 2000 to 2017 – a Nationwide Study of Danish Register Data
12:00-12:30	OP-27	NICOLE KOZLOFF (Toronto, Ontario, Canada) - Adapting Community Reinforcement Approach and Family Training to Target Substance Use in Early Psychosis Intervention (Craft-Epi): A Pilot Study
11:00-12:30	ROOM D	S22 - ASSESSING DUAL DISORDER HEROIN ADDICTS <i>Chair: Mario Miccoli (Pisa, Italy, EU)</i>
11:00-11:30	S22-1	ICRO MAREMMANI (Pisa, Italy, EU) - Is the Psychopathology of Dual Disorder Heroin Addicts Different from Heroin Use Disorder Psychopathology?
11:30-12:00	S22-2	ANGELO GIOVANNI ICRO MAREMMANI (Viareggio, Italy, EU) - Hero-Crav in Heroin Use Disorder Patients with and without Dual Disorder
12:00-12:30	S22-3	FILIPPO DELLA ROCCA (Pisa, Italy, EU) - H/PTSD-S in Dual Disorder Heroin Addicts
○ CONFERENCE		
12:30-13:30	ROOM A	CONFERENCE 7 <i>Chair: Marta Torrens (Barcelona, Spain, EU)</i>
12:30-13:30	CF-11	YIFRAH KAMINER (Farmington, CT, USA) - Treatment of Youth with Dual Disorder of Substance Use Disorder and Depression: A Bi-Center Study
13:30-14:30	CF-12	DAVID NUTT (London, UK) - Psychedelics in the Treatment of Dual Disorders: Addiction and Other Mental Disorders
14:30-15:00	CLOSING REMARKS	NESTOR SZERMAN (Madrid, Spain, EU) - Closing remark and see you in Palma de Mallorca (Spain)

○ POSTERSESSION

P01	Íñigo ALBERDI-PÁRAMO, Marta PÉREZ-LOMBARDO, Jesús IBÁÑEZ-VIZOSO, Jesús PEMÁN-RODRÍGUEZ, José RIDRÍGUEZ-QUIJANO, Marta SÁNCHEZ-AMORES and Germán MONTERO-HERNÁNDEZ (Madrid, Spain, EU) - Association between Suicidal Behavior and Non-Suicidal Self-Injury in Bpd Tobacco Smokers: A Retrospective Study.
P02	Ottone BACCAREDDA BOY, Giuseppe Pierpaolo MEROLA, Davide ARILLOTTA, Alessandra FRANCO, Giulia BORGIOI, Carlotta BERTOCCI, Niccolò PORCINAI, Andrea BALLERINI and Brunella OCCUPATI (Milano, Italy, EU) - Joint Mental-Health and Drug Health Assessment and Follow-up Unit in a Public Healthcare Setting in Italy.
P03	Ignacio BASURTE-VILLAMOR, Pablo VEGA ASTUDILLO, Inés DE EMA LÓPEZ and Nestor SZERMAN (Madrid, Spain, EU) - A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment.
P04	Igna BRAJEVIC-GIZDIC and Magda PLETIKOSA PAVIC (Split, Croatia, EU) - Treatment of Opiate Addicted Veterans with Ptsd and a Chronic Hepatitis C Comorbidity, More Than 25 Years after the War.
P05	Alicia CAPILLA CRESPILO, Cristina PUJOL RIERA, Anna BARNES ANDREU, Abigaïl JUBERT FORNELL and Isabel Maria PARRA URIBE (Sabadell, Spain, EU) - The Role of Substance Use Disorder in Consultation-Liaison Psychiatry in a General Hospital.
P06	Deschenau ALICE and Al Tabchi AMIR (Villejuif, France, EU) - Clinical and Social Feedback from Patients Who Initiated Long-Acting Buprenorphine in a French Addiction Center.
P07	Silvia DIAZ-FERNANDEZ, Juan J. FERNANDEZ-MIRANDA and Francisco PASCUAL-PASTOR (Gijón, Spain, EU) - Gender and Substance Use and Other Mental Disorders Comorbidity. Sociodemographic, Clinical and Treatment Differences.
P08	Juan J. FERNANDEZ-MIRANDA, Silvia DIAZ-FERNANDEZ and Francisco PASCUAL-PASTOR (Gijón, Spain, EU) - Co-Occurrence of Substance Use Disorders and Other Mental Disorders in People Undergoing Specific Treatment for Any of Them in Spain.
P09	Alexandra GARCIA -GUIX, Marta NAYACH, Lina OVIEDO, Gerard MATEU-CODINA, Francina FONSECA-CASALS, Rosa SAURAS-QUETCUTI, Maria ROBLES, Estefania LOPEZ and Marta TORRENS (Santa Coloma de Gramenet, Spain, EU) - Characterization of Women with and without Dual Diagnosis Attended in an Outpatient Addiction Centre in Barcelona During the Period between 2017-2022.
P10	Sergey IGUMNOV and Lapanov PAVEL (Minsk, Belarus - Gomel, Belarus) - Alexithymia as a Risk Factor of Addictive Behavior.
P11	Sameer Ul Khaliq JAN (Wari, Upper Dir, Pakistan, PK) - Causes and Effects of the Combination of Heroin and Methamphetamine on the Addicts: A Study of Khyber Pakhtunkhwa, Pakistan.
P12	Katrine Schepelern JOHANSEN (Roskilde, Denmark, EU) - What Differences Can Dedicated Nurses Do for Dual Diagnosis Patients? A Qualitative Research Project of 'Social Nurses' in Denmark.
P13	Jakob KRARUP (Roskilde, Denmark, EU) - Reducing Coercion in Integrated Dual Diagnosis Treatment.
P14	Jakob KRARUP (Roskilde, Denmark, EU) - The Emerging Danish National Plan for Integrated Treatment of Dual Diagnosis Patients.
P15	Barbara LOVRECIC, Laura PETRIC and Mercedes LOVRECIC (Ljubljana, Slovenia, EU) - Impact of Pandemia Covid 19 on Dual Disorders.
P16	Barbara LOVRECIC, Mercedes LOVRECIC, Angelo G.I. MAREMMANI and Icro MAREMMANI (Ljubljana, Slovenia, EU) - Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health.
P17	Ricardo MARTINEZ GALLARDO, Beatriz VALIENTE PEÑA, Noelia HERNANDEZ VICENTE and Andrea MARTINEZ ABELLA (Soria, Spain, EU) - Metabolic Syndrome in Psychotic Patients Treated with Nap and Substance Users.
P18	Ricardo MARTINEZ GALLARDO, Noelia HERNANDEZ VICENTE, Andrea MARTINEZ ABELLA and Beatriz VALIENTE PEÑA (Soria, Spain, EU) - Consumption Pattern in Psychotic Patients According to the Type of Treatment.
P19	Ricardo MARTINEZ GALLARDO, Andrea MARTINEZ ABELLA, Beatriz VALIENTE PEÑA and Noelia HERNANDEZ VICENTE (Soria, Spain, EU) - How Does the Consumption of Toxins Affect the Cognitive State of Psychotic Patients?
P20	Germán MONTERO-HERNANDEZ, Iñigo ALBERDI-PÁRAMO, Marta PÉREZ-LOMBARDO, Jesús PEMÁN-RODRÍGUEZ and José RODRÍGUEZ QUIJANO (Bilbao, Spain, EU) - Results of the Use of Cariprazine in the Treatment of Schizophrenia and Substance Use Disorder. A Case Series in Both Inpatient and Outpatient Regime.
P21	Shahram NADERIMAZEJIN (Teheran, Iran, IR) - A Critique on the Way to Administer Oxytocin in Studies Related to Addiction and Co-Occurring Dual Disorders.

P22	Shahram NADERIMAZEJIN (Tehran, Iran, IR) - An Evolutionary Look at Oxytocin and Testosterone.
P23	Kinga NOBLE (Lanark, UK) - Integration of Co-Occurring Mental Health Difficulties into Substance Use Care in Lanarkshire: Service Users' Perspectives on Their Psychiatric Needs' Attention and Management.
P24	Silje NORD-BAADE, Ottar NESS, Michael ROWE, Camilla B. JENSEN and Anne LANDHEIM (Ottestad, Norway, NOR) - How to Matter: Promoting Social Inclusion and Participation among Young Adults with Complex Problems in Fact Teams.
P25	Raul Felipe PALMA-ALVAREZ, Constanza DAIGRE, Elena ROS-CUCURULL, German ORTEGA-HERNANDEZ, Ana RIOS-LANDEO, Paula GAMBOA, Patricia SANAZARIO, Carlos RINCERO, Josep Antoni RAMOS-QUIROGA and Lara GRAU-LOPEZ (Barcelona, Spain, EU) - Clinical Features and Factors Related to Lifetime Suicidal Ideation in Adult Adhd Patients with Substance Use Disorders.
P26	Marc PERAIRE, Francesc RODRÍGUEZ-RUIZ, Francisco ARNAU-PEIRÓ, Ana BENITO, Jorge RENAU and Gonzalo HARO (Castellon de la Plana, Spain, EU) - Antidepressant Effectiveness of Clozapine, During a Month of Follow-up, in Dual Psychosis.
P27	Marta PÉREZ-LOMBARDO, Íñigo ALBERDI-PÁRAMO, Jesús PEMÁN-RODRÍGUEZ, José RODRÍGUEZ-QUIJANO, Ana GARCÍA-CARPINTERO, Arturo GONZÁLEZ-CASTELLARY and Germán MONTERO-HERNÁNDEZ (Madrid, Spain, EU) - I Have Psychosis but, What About My Addiction? Use of Cariprazine in Dual Disorders.
P28	Francesc RODRÍGUEZ RUIZ, Marc PERAIRE, Francisco ARNAU-PEIRÓ, Ana BENITO, Jorge RENAU and Gonzalo HARO (Castellón de la Plana, Spain, EU) - Efficacy and Tolerability of Clozapine in Dual Psychosis During a Month of Follow-Up.
P29	Danica ROMAC, Boris GRACIN, Zrinka ČAVAR, Mirjana ORBAN and Marija KUŠAN JUKIĆ (Zagreb, Croatia, EU) - Substance Use Trends and Treatment Demands.
P30	Anat SASON, Miriam ADELSON and Einat PELES (Tel Aviv, Israel) - Immigrants from Russian and Outcome in Methadone Maintenance Treatment.
P31	Rosa Blanca SAURAS QUETCUTI, Gerard Mateu CODINA, Ana Maria CORATU, Daniel GARCIA-FUENTES, Alexandra GARCIA-GUIX, Maria ROBLES, Lina OVIEDO, Claudio CASTILLO, Marta TORRENS and Maria Francina FONSECA (Barcelona, Spain, EU) - From Methamphetamine Induced Psychosis to Schizophrenia: A Study of Diagnostic Stability in Dual Pathology Units of Parc De Salut Mar in Barcelona.
P32	Laura SOVERCHIA, Federica BENVENUTI, Esi DOMI, Massimo UBALDI, Nazzareno CANNELLA and Roberto CICCOCIO PPO (Camerino, Italy, EU) - Early Social Isolation as a Vulnerability Factor Affecting Alcohol Abuse Trajectory in Genetically-Selected Alcohol-Preferring and Non-Preferring Rats.
P33	Aneta SPASOVSKA TRAJUANOVSKA (Skopje, North Macedonia) - Risperidone in Treatment Methadone Maintenance Patients with Dual Diagnosis.
P34	Lilijana ŠPRAH (Ljubljana, Slovenia, EU) - Psychiatric Readmission and Physical Comorbidity.
P35	Gabriel THORENS, Louise PENZENSTADLER and Daniele ZULLINO (Geneve, Switzerland) - Psychedelic Assisted Psychotherapy for a Patient with Thc Addiciton and Recurrent Depressive Disorder.

FACULTY	
SERGE AHMED	Choice, Addiction and Neurodysfunctions (Candy), Bordeaux Neurocampus, Bordeaux, France, EU.
MUSTAFA AL'ABSI	University of Minnesota Medical School, Duluth, MN, USA.
DERVAUX ALAIN	Paul Brousse Hospital - Paris Saclay University, Villejuif, France, EU.
INIGO ALBERDI-PARAMO	Hospital Clínico San Carlos, Madrid, Spain, EU.
EMANUELA ATZORI	MAGMA ODV; FUORI PASSO ETS , Rome, Italy, EU.
OTTONE BACCAREDDA BOY	University of Florence, Italy, EU.
RUBEN BALER	National Institute of Drug Abuse, Rockville, ML, USA.
YATAN PAL SINGH BALHARA	All India Institute of Medical Sciences, New Delhi, Delhi, India.
IGNACIO BASURTE-VILLAMOR	Department of Psychiatry and Behavioral Health, Clínica López Ibor, Madrid, Spain, EU
LISA BLECHA	Paul Brousse Hospital - Paris Saclay University, Villejuif, France, EU.
IGNA BRAJEVIC-GIZDIC	Public Health Institute of Split - Dalmatia County, Mental Health Service, Split, Croatia, EU.
EVA BREKKE	Norwegian National Advisory Unit on Concurrent Mental Health and Substance Use Disorders, Hamar, Norway.
ROMEO BRUNO	Paul Brousse Hospital - Paris Saclay University, Villejuif, France, EU.
NAZZARENO CANNELLA	School of Pharmacy, University of Camerino, Italy, EU.
ALICIA CAPILLA CRESPILO	Parc Taulí Hospital Universitari, Sabadell, Spain, EU, Sabadell, Spain, EU
MANUEL GLAUCO CARBONE	Research Doctorate, Insubria University, Varese, Italy, EU.
SEBASTIEN CARNICELLA	Grenoble Institute of Neurosciences, Grenoble, France, EU.
NADER CHARKHGARD	Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran, Iran.
ROBERTO CICCOCIOPPO	School of Pharmacy, Center for Neuroscience, Pharmacology Unit. University of Camerino, Italy, EU.
LUDOVICA COSTANTINO	MAGMA ODV; FUORI PASSO ETS , Rome, Italy, EU.
FABIO CURCIO	ASL Napoli 1 Centro - Department of Addiction, Napoli, Italy, EU.
PINHAS DANNON	Hebrew University of Jerusalem, Herzog Medical Center, Jerusalem, Israel.
FILIPPO DELLA ROCCA	PISA School of Addiction Medicine, Institute of Behavioural Sciences, Pisa, Italy, EU.
MAURICE DEMATTEIS	Department of Pharmacology and Addiction Medicine, Grenoble-Alpes University Hospital, Grenoble, France, EU.
ALICE DESCHENAU	Groupe Hospitalier Paul Guiraud, Villejuif, France, EU.
SILVIA DIAZ-FERNANDEZ	Agc Smental V. Hospital De Cabueñes. Sº De Salud Del Pº De Asturias-Sespa, Gijón, Spain, EU
JULIEN DUBREUCQ	Department of Child-Adolescent Psychopathology, University Hospital of Saint Etienne, France, EU.
DANIEL FEINGOLD	Psychology Department, Ariel University, Ariel, Israel, Nataf, Israel.
JUAN J. FERNANDEZ-MIRANDA	Asturian Mental Health Service, Gijón, Spain, EU.
ZOE FRIEDMANN	Charite Berlin, Berlin, Germany, EU.
ALEXANDRA GARCIA-GUIX	Parc de Salut Mar-Institute de Neuropsychiatryand Addictions (INAD), Santa Coloma de Gramenet, Spain, EU.

OR GLIKSBERG	Psychology Department, Ariel university, Israel , Nataf, Israel, IL.
BARD GRONSTOL	Vestfold Hospital Health Authority, Norway.
JIBRIL IBRAHIM MOUSSA HANDULEH	Amoud University , Borama, Somalia.
GONZALO HARO	Cardenal Herrera-CEU University, Castellón de la Plana, Spain, EU.
JOAKIM HAUGE	Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Brumunddal, Norway.
ADA HOČEVAR GROM	Skopje University, North Macedonia.
LILJANA IGNJATOVA	Faculty of Medicine, Department for Psychiatry, Skopje, North Macedonia.
SERGEY IGUMNOV	Institute of Psychology, Belarusian Pedagogical University, Minsk, Belarus.
SARA JAFARI	School of Advanced Technologies In Medicine, Tehran Medical University, Tehran, Iran.
SAMEER UL KHALIQ JAN	Shaheed Benazir Bhutto University, Sheringal, Wari, Upper Dir, Pakistan.
KATRINE SCHEPELERN JOHANSEN	Competence Centre of Dual Diagnosis, Mental Health Services Capital Region, Denmark, Roskilde, Danmark, EU.
ZUZANA KAMENDY	Centre for Treatment of Drug Dependencies Bratislava, Slovakia, EU.
YIFRAH KAMINER	University of Connecticut, School of Medicine, Farmington, CT, USA.
ALEXANDER KANTCHELOV	The Kantchelov Clinic, Sofia, Bulgaria, EU.
KHADIJA KARJOUH	Laboratory of Biology and Health, Department of Biology, Faculty of Science, IBN Tofail University, Kenitra, Morocco.
ARI KASKI	Kuopion Päihdepalvelusäitiö, Kuopio, Finland, EU.
SAMIR SHIMON KASPER	Inpatient Department in Cantonal Institute of Addiction, Zenica, Bosnia and Herzegovina.
GORDANA KITEVA TRENCEVSKA	Faculty of Medicine, Department for Psychiatry, Skopje, North Macedonia.
NICOLE KOZLOFF	Centre for Addiction and Mental Health CAMH Toronto, Ontario, Canada.
JAKOB KRARUP	Mental Health Services Capital Region, Roskilde, Danmark, EU.
ADAM KURILLA	Centre for Treatment of Drug Dependencies Bratislava, Slovakia, EU.
ANNE LANDHEIM	Norwegian National Center for Concurrent Substance Abuse and Psychiatric Disorders, Hamar, Norway,.
KUNHUA LEE	Department of Educational Psychology and Counseling, National Tsing Hua University, Hsinchu City, Taiwan.
MARJA LEONHARDT	Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Brumunddal, Norway.
BARBARA LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU.
MERCEDES LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU.
MARCO MAIELLO	Department of Psychiatry and Addictions, Section of Addiction, North-Western Tuscany Local Health Unit, Tuscany NHS, Apuan Zone, Massa, Italy, EU.
LOPEZ RAFAEL MALDONADO	University Pompeu Fabra, Barcelona, Spain, EU.
ANGELO GIOVANNI ICRO MAREMMANI	Department of Psychiatry and Addictions, Section of Psychiatry, North-Western Tuscany Local Health Unit, Tuscany NHS, Versilia Zone, Viareggio, Italy EU.

ICRO MAREMMANI	University of Pisa, and UniCamillus, International Medical University in Rome, Italy, EU.
BERNADETTE MARSON	Adelphi University, Fredonia, United States of America, USA.
SOLVEJ MÅRTENSSON	Competency Center for Dual Diagnosis, Mental Health Services, Capital Region Of Denmark, Roskilde, Danmark, Eu.
ELENA MARTIN-GARCIA	Laboratory of Neuropharmacology, Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Parc de Recerca Biomédica de Barcelona (PRBB), Barcelona, Spain, EU.
RICARDO MARTINEZ GALLARDO	SPsychiatric Service at SACYL Logroño and surroundings, Soria, Spain, EU.
GERMAN MONTERO-HERNANDEZ	Red Salud Mental Bizkaia - Osakidetza, Bilbao, Spain, EU.
MICKAEL NAASSILA	University of Picardie Jules Verne, INSERM UMRS, Amiens, France.
SHAHRAM NADERI	School of Advanced Technologies in Medicine, Tehran Medical University, Tehran, Iran.
SHAHRAM NADERIMAZEJIN	School of Advanced Technologies in Medicine, Tehran Medical University, Tehran, Iran.
PETR NEVŠÍMAL	Magdaléna, o.p.s., Praha 8, Czech Republic, EU.
SAMAN NIKNEJAD NIKNEJAD	Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran, Iran.
KINGA NOBLE	University of the West of Scotland, Lanark, United Kingdom.
DAVID NUTT	Faculty of Medicine, Department of Brain Sciences, Imperial College, London, Uk.
LUBOMÍR OKRUHLICA	Centre for Treatment of Drug Dependencies Bratislava, Slovakia, EU.
MATTEO PACINI	V.P. Dole Research Group, G. De Lisio Institute of Behavioural Sciences, Pisa, Italy, EU.
ALESSANDRO PALLUCCHINI	Department of Psychiatry and Addictions, Section of Addiction, North-Western Tuscany Local Health Unit, Tuscany NHS, Apuan Zone, Massa, Italy, EU.
RAUL FELIPE PALMA-ALVAREZ	Hospital Universitari Vall d'Hebron, Barcelona, Spain, EU, Barcelona, Spain, EU
VAIBHAV PATIL	All India Institute of Medical Sciences, New Delhi, New Delhi, India.
EINAT PELES	Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, IL.
LUCIE PENNEL	Department of Addiction Medicine, Grenoble-Alpes University Hospital, Grenoble, France.
LOUISE PENZENSTADLER	The Geneva Compassionate Use Program, Geneva, Switzerland.
MARC PERAIRE	Consorcio Hospitalario Provincial de Castellón, Castellon de la Plana, Spain, EU.
MARTA PÉREZ-LOMBARDO	Hospital Clínico San Carlos, Madrid, Spain, EU
PAYMAN RAAD	Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran, Iran, IR.
ILARIO RITACCO	MAGMA ODV; FUORI PASSO ETS, Rome, Italy, EU.
FRANCESC RODRÍGUEZ RUIZ	Consorci Hospitalari Provincial de Castellón, Castellón, Spain, EU.
DANICA ROMAC	Institute of Public Health "Andrija Štampar", Zagreb, Croatia, EU
CARLOS RONCERO	Salamanca University, Spain, EU.
INIGO RUIZ DE AZUA	Leibniz Institute for Resilience Research, Mainz, Germany, EU

CAROLINE SALOM	University of Queensland, Brisbane, Queensland, AU. .
SIDDHARTH SARKAR	All India Institute of Medical Sciences, New Delhi, New Delhi, India.
ANAT SASON	Tel Aviv Medical Center, Tel Aviv, Israel.
ROSA BLANCA SAURAS QUETCUTI	Parc de Salut Mar, Barcelona, Spain, EU.
CHRISTIAN SCHUTZ	Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
VIJAY SEETHAPATHY	UBC, Vancouver, Canada, CAN.
LEO SHER	Mount Sinai School of Medicine, New York, NY, USA.
LORENZO SOMAINI	Addiction Department, Biella, Italy, EU.
LAURA SOVERCHIA	University of Camerino, camerino, Italy, EU, camerino, Italy, EU
ANETA SPASOVSKA TRAJUANOVSKA	Faculty of Medicine, Department for Psychiatry, Skopje, North Macedonia.
VINCENZA SPERA	Psychiatric Hospital, Sociopsychiatric Organization, Mendrisio, Switzerland.
LILIJANA ŠPRAH	Znanstvenoraziskovalni Center SAZU, Ljubljana, Slovenia, EU.
TSVETANA STOYKOVA	The Kantchelov Clinic, Sofia, Bulgaria, EU.
NESTOR SZERMAN	Complutense University, Madrid, Spain, EU.
GABRIEL THORENS	Geneva university hospital, geneve, Switzerland, CHE, Geneva, Switzerland
MARTA TORRENS	University of Barcelona, Spain, EU.
ALBRECHT ULMER	Institute for Addiction Research, Stuttgart, Germany, EU.
SARAH VECCHIO	Department of Addiction Medicine, Biella, Italy, EU.
PABLO VEGA	Universidad Cardenal Herrera-CEU, CEU Universities, Castellón de la Plana, Spain, EU.
NORA VOLKOW	National Institute of Drug Abuse, Rockville, ML, USA
SÉBASTIEN WEIBEL	Department of Psychiatry, University Hospital of Strasbourg, France, EU.
CHRISTOPHER WURM	University of Adelaide, Prospect East, Australia.
DANIELE ZULLINO	Faculty of Medicine, Geneva University Hospitals, Department of Psychiatry, Geneva, Switzerland.



PISA ROVAI SCHOLARS AWARD
"The Luca Rovai Award"
"Dedicated to all those who dream of a better world for drug addicts"

Rovai Scholars award, named after one of the founding member of PISA-School of Addiction Medicine Dr. Luca Rovai is a prestigious title in the field of Psychiatry and Addiction Medicine granted by the PISA-School of Addiction Medicine and the Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS) to a select group of promising residents in Psychiatry and Addiction Medicine and young specialists in these fields.

FORMER RECIPIENTS:

From Intense to Occasional Use of Cocaine in Dual Disorder (ADHD/Cocaine Use Disorder) Patients Treated with Stimulant Medications by C. Manni, A. Pallucchini, G. Cipollone, V. Spera, M. Maiello, M. Novi, G. Perugi and I. Maremmani. Poster presented at "New paradigms for mental disorders: Neurodevelopmental, neuroprogressive and neurodegenerative perspectives" Pisa, Italy, October 22-23 2018

High Risk Drinking and Prescription Drug Misuse: Relationship with Suicidal Ideation among US National Guard Soldiers by F. C. Blow, R. V. Ignacio, R. McCormick, M. A. Walton, A. S. B. Bohnert, M. A. Ilgen. Poster presented at 2° World Congress of the World Association on Dual Disorders (WADD), Florence, October 25-27 2018

Naturalistic Follow-up in Bipolar Patients after Successful Electroconvulsive Therapy by M. Novi, M. Barbuti, B. Tripodi, A. Boccolini, G. Gemmellaro, F. De Dominicis, C. Elefante, L. Lattanzi, P. Medda, and G. Perugi. Poster presented at Neurodevelopmental Psychopathology in Adults: Depressive, Bipolar, Psychotic and Substance Use Disorders, Pisa, Italy, EU, July, 8-9 2019

High therapeutic buprenorphine levels reduce i.v. fentanyl respiratory depression by M. G. Tocco, K. Wiest, M. H. Algera, L. Moss, M. van Velzen, G. J. Groeneveld, J. Heuberger, A. Dahan, F. Gray, S. Strafford, R. Dobbins. Poster presented at 14th EUROPAD European Congress, Grenoble, France, November 19-21, 2021

Early experience of buprenorphine long-acting injection in Finland. A retrospective cohort study by M. Partanen, T. Saarenpää, T. Prami, I. Iso-Mustajärvi, B. Ryder and K. Simojoki. Poster presented at 15th European Congress of EUROPAD, Pisa, Italy, May 20-22, 2022



camurus®

 GEDEON RICHTER

 **MOLTENI**[®]
FARMACEUTICI 1892 | 2017

 **RECORDATI**